Saleh Rachidi1, Shaoli Sun2, Bill X Wu1, Elizabeth Jones3, Richard R Drake3, Besim Ogretmen4, L Ashley Cowart5, Christopher J Clarke6, Yusuf A Hannun6, Gabriela Chiosis7, Bei Liu1, Zihai Li8. 1. Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC, United States; Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, United States. 2. Department of Pathology, Medical University of South Carolina, Charleston, SC, United States. 3. Department of Cell and Molecular Pharmacology, Medical University of South Carolina, Charleston, SC, United States. 4. Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, SC, United States. 5. Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, SC, United States; Ralph H. Johnson Veteran's Affairs Medical Center, Charleston, SC, United States. 6. Department of Medicine, Stony Brook University, Stony Brook, NY, United States. 7. Program in Molecular Pharmacology and Chemistry, Memorial Sloan-Kettering Cancer Center, New York, NY, United States. 8. Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC, United States; Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, United States. Electronic address: zihai@musc.edu.
Abstract
BACKGROUND & AIMS: gp96, or grp94, is an endoplasmic reticulum (ER)-localized heat shock protein 90 paralog that acts as a protein chaperone and plays an important role for example in ER homeostasis, ER stress, Wnt and integrin signaling, and calcium homeostasis, which are vital processes in oncogenesis. However, the cancer-intrinsic function of gp96 remains controversial. METHODS: We studied the roles of gp96 in liver biology in mice via an Albumin promoter-driven Cre recombinase-mediated disruption of gp96 gene, hsp90b1. The impact of gp96 status on hepatic carcinogenesis in response to diethyl-nitrosoamine (DENA) was probed. The roles of gp96 on human hepatocellular carcinoma cells (HCC) were also examined pharmacologically with a targeted gp96 inhibitor. RESULTS: We demonstrated that gp96 maintains liver development and hepatocyte function in vivo, and its loss genetically promotes adaptive accumulation of long chain ceramides, accompanied by steatotic regeneration of residual gp96+ hepatocytes. The need for compensatory expansion of gp96+ cells in the gp96- background predisposes mice to develop carcinogen-induced hepatic hyperplasia and cancer from gp96+ but not gp96- hepatocytes. We also found that genetic and pharmacological inhibition of gp96 in human HCCs perturbed multiple growth signals, and attenuated proliferation and expansion. CONCLUSIONS: gp96 is a pro-oncogenic chaperone and an attractive therapeutic target for HCC.
BACKGROUND & AIMS:gp96, or grp94, is an endoplasmic reticulum (ER)-localized heat shock protein 90 paralog that acts as a protein chaperone and plays an important role for example in ER homeostasis, ER stress, Wnt and integrin signaling, and calcium homeostasis, which are vital processes in oncogenesis. However, the cancer-intrinsic function of gp96 remains controversial. METHODS: We studied the roles of gp96 in liver biology in mice via an Albumin promoter-driven Cre recombinase-mediated disruption of gp96 gene, hsp90b1. The impact of gp96 status on hepatic carcinogenesis in response to diethyl-nitrosoamine (DENA) was probed. The roles of gp96 on humanhepatocellular carcinoma cells (HCC) were also examined pharmacologically with a targeted gp96 inhibitor. RESULTS: We demonstrated that gp96 maintains liver development and hepatocyte function in vivo, and its loss genetically promotes adaptive accumulation of long chain ceramides, accompanied by steatotic regeneration of residual gp96+ hepatocytes. The need for compensatory expansion of gp96+ cells in the gp96- background predisposes mice to develop carcinogen-induced hepatic hyperplasia and cancer from gp96+ but not gp96- hepatocytes. We also found that genetic and pharmacological inhibition of gp96 in human HCCs perturbed multiple growth signals, and attenuated proliferation and expansion. CONCLUSIONS:gp96 is a pro-oncogenic chaperone and an attractive therapeutic target for HCC.
Authors: Pengrong Yan; Hardik J Patel; Sahil Sharma; Adriana Corben; Tai Wang; Palak Panchal; Chenghua Yang; Weilin Sun; Thais L Araujo; Anna Rodina; Suhasini Joshi; Kenneth Robzyk; Srinivasa Gandu; Julie R White; Elisa de Stanchina; Shanu Modi; Yelena Y Janjigian; Elizabeth G Hill; Bei Liu; Hediye Erdjument-Bromage; Thomas A Neubert; Nanette L S Que; Zihai Li; Daniel T Gewirth; Tony Taldone; Gabriela Chiosis Journal: Cell Rep Date: 2020-06-30 Impact factor: 9.423
Authors: Mieke Baan; Carly R Kibbe; Justin R Bushkofsky; Ted W Harris; Dawn S Sherman; Dawn Belt Davis Journal: Am J Physiol Regul Integr Comp Physiol Date: 2015-07-22 Impact factor: 3.619
Authors: Ephraim A Ansa-Addo; Jessica Thaxton; Feng Hong; Bill X Wu; Yongliang Zhang; Caroline W Fugle; Alessandra Metelli; Brian Riesenberg; Katelyn Williams; Daniel T Gewirth; Gabriela Chiosis; Bei Liu; Zihai Li Journal: Curr Top Med Chem Date: 2016 Impact factor: 3.295